OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 OutpatientsGlobeNewsWire • 08/30/21
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School' COVID-19 Testing ProgramBusiness Wire • 08/26/21
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing BusinessPRNewsWire • 08/16/21
OPKO Health, Inc. (OPK) CEO Phillip Frost on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial ResultsGlobeNewsWire • 07/29/21
Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to DeclineZacks Investment Research • 07/22/21
OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant EpilepsyBenzinga • 07/12/21
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 TherapeuticsGlobeNewsWire • 07/12/21